Viral Clearance Market size in 2019 is estimated to be $280 million, growing at a CAGR of 21.5% during the forecast period 2020-2025. Viral clearance is an essential process in development for monoclonal antibodies, recombinant proteins and glycoproteins, tissue and blood-derived products and medical devices. Viral clearance is an important process during the downstream purification of therapeutic biologics, blood, and tissue-derived products. Increasing prevalence of chronic viral infections and technological advancement are the major factors driving the growth of the market. Moreover, rising geriatric population, increasing R&D activities and increasing healthcare expenditure further enhance the overall market demand for viral clearance during the forecast period 2020-2025.
Key Takeaways
- In 2019, North America dominates the viral clearance market owing to advanced healthcare infrastructure, advanced instruments and technologies and increasing healthcare expenditure.
- Increasing prevalence of chronic viral infections and technological advancement is driving the market growth of viral clearance.
- Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the viral clearance market report.
- High cost of technology and lack of skilled professional are challenging the growth of the market.
Method - Segment Analysis
Based on the Method, Viral Clearance Market is segmented into viral removal, viral inactivation. Viral Removal segment is forecast to be the fastest-growing segment and is estimated to grow at a CAGR of 18% during the forecast period 2020-2025. This is mainly owing to high accuracy, speed, and flexibility provided by the method in life sciences research, and increasing acceptance of the method in the industry. Moreover, growth in R&D activities for the development of this method are contributing the growth of this segment.
End-Use Industries - Segment Analysis
Based on the End-Use Industries, Viral Clearance Market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Others. In 2019, pharmaceutical & biotechnology companies held the largest share in the viral clearance market. This is mainly owing to increased usage of these products for the purpose of drug development and drug manufacturing that are contributing to the growth of this segment.
Geography - Segment Analysis
North America dominated the viral clearance market share accounting for 40% of the market in 2019. This is mainly owing to advanced healthcare infrastructure, advanced instruments and technologies and increasing healthcare expenditure. According to U.S. Food and Drug Association, vital clearance has been made mandatory step for investigation of new drugs in the view of safety concerns that are contributing the growth of this market.
However, the Asia-Pacific region is forecast to be the fastest-growing during the forecast period 2020-2025. This is owing to the growth in healthcare infrastructure and rising awareness among people about disease.
Drivers – Viral Clearance Market
- Increasing Prevalence of Chronic Viral Infection
Rising prevalence of chronic viral infections and diseases is increasing demand for efficient treatment method are some factors driving the growth of viral inactivation market. Moreover, increase investment in the life science sector, rising number of new drug launches and increase in R&D innovation are also set to increase the market growth.
- Technological Advancements
Technological Advancements and increasing healthcare expenditure are some factors driving the growth of the market. Moreover, technological evolution in the medical industry increasing the demand for viral clearance process and developing new & enhanced therapies to tackle the rise in many diseases such as nano filtration technology and increasing drug discoveries further contributing the growth of viral clearance market.
Challenges – Viral Clearance Market
High cost associated with the development of products and technology and lack of skilled professional are challenging the growth of the market. Moreover, time-consuming process of drug development and some problems associated with the virus clearance process such as virus aggregate formulation, protein crosslinking and protein denaturation and degradation are further restraining its market growth during the forecast period 2020-2025.
Viral Clearance Industry Outlook
Product launches, Merger & Acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Viral Clearance Market. Viral Clearance top 10 companies are Merck KGaA, Danaher corporation, Sartorius AG, Charles River, SGS SA, PARKER HANNIFIN CORP, Clean Cells, Rad Source Technologies, Texcell and WuXi AppTec.
Acquisitions/Product Launches
- On 27 September 2019, Merck KGaA has acquisition with Pfizer Inc. and launches new drug BAVENCIO for the removal of virus and also helps to treat many diseases such as cancers including, renal cell carcinoma, metastatic and many more.
- On 1 March 2019, Clean Cells has acquisition with NAOBiOS for the development of viral vaccines and used for the treatment of many diseases.
